Financial Post EN

Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma

PARIS, FRANCE, 09 March 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik® (tazemetostat) in all indications from all Ipsen markets. Ipsen’s decision to withdraw is based on emerging data from the ongoing Phase Ib/III SYMPHONY-1 trial (evaluating tazemetostat in combination with lenalidomide plus rituximab (R2) vs R2 in follicular […]

Mar 09, 2026 &03010909202631; 06:01 UTC financialpost.com

Read original on financialpost.com ↗

↘

Negative for markets

Sentiment score: -75/100

High impact Immediate effect (hours)

WHAT THIS MEANS

Ipsen voluntarily withdraws Tazverik (tazemetostat) from all markets across all indications due to emerging safety or efficacy concerns from the SYMPHONY-1 trial. This represents a significant setback for the company's oncology portfolio and will likely impact revenue and investor confidence in its pipeline.

AI CONFIDENCE

85% Very high

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↓

IPN

IPNStock

Expected to decline

Voluntary withdrawal of marketed drug Tazverik eliminates revenue stream and signals clinical trial failure; negative impact on earnings and pipeline credibility

↓

EU→.PA

EU→.PAIndex

Expected to decline

Ipsen is a major pharmaceutical constituent; negative company-specific news may weigh on European healthcare sector sentiment

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Sell IPN on any strength; monitor for additional pipeline setbacks and management guidance revisions. Consider hedging exposure to European pharma sector until clinical trial details are disclosed.

KEY SIGNALS

Drug withdrawal from all marketsPhase Ib/III trial emerging data concernsLoss of revenue from follicular lymphoma and epithelioid sarcoma indicationsPotential regulatory or safety issuesPipeline credibility questioned

SECTORS INVOLVED

HealthcarePharmaceuticalsBiotechnology

Analysis generated on Mar 09, 2026 at 14:55 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Financial Post. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma

RELATED INTELLIGENCE